Organization
Portola Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Portola Pharmaceuticals, Inc.
... SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) ...
... patient, 450-site Phase 3 trial he led across 30 countries while at Portola that resulted in the approval of Betrixaban. Dr. Daly's clinical operations expertise, ...
... Portola Pharmaceuticals, Inc., announced that its chief commercial officer Tao Fu has resigned effective ...
... SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Tao Fu, chief commercial officer, has ...
... patient, 450-site Phase 3 trial he led across 30 countries while at Portola that resulted in the approval of Betrixaban. Dr. Daly's clinical operations expertise, ...
... SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee ...
... Shutterstock, Inc. (NYSE:SSTK), CrossAmerica Partners LP (NYSE:CAPL), Allegiance Bancshares, Inc. (NASDAQ:ABTX), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), StoneMor Partners L.P. (NYSE:STON), and Catalyst Biosciences, Inc. (NASDAQ:CBIO), including ...
... SOUTH SAN FRANCISCO - Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) ...
Subscribe now for full coverage on Portola Pharmaceuticals, Inc.
Start My Free Trial